Modernizing Mental Health Through Innovative Technology & Psychedelics
Mydecine Innovations Group Inc. (CNSX: MYCO) (OTCMKTS: MYCOF) (FSE:0NF) and its subsidiary MindLeap Health have built an advanced digital health platform that helps people connect with mental health specialists that can empower them to thrive and develop habits for a healthy mind.
MindLeap supports people looking to achieve personal transformations and overcome mental health challenges—it's the only platform the combines Telehealth and tracking.
Health & Recovery Coaching
Assist people in translating psychedelic experiences into positive changes that overcome addiction.
Track Your Mental Health
Track your mood, emotions, habits and progress towards improved well-being over time.
Investment Highlights
Massive Market Size
More than 300 million people suffer from depression worldwide, while the telemedicine market is estimated to be worth upwards of $30 billion—growing at a ~20% CAGR through 2025.
Near-term Launch
MindLeap's software platform was designed by leading psychologists and neuroscientists and is set to launch in the third quarter of 2020, providing a near-term catalyst for investors.
Mydecine Acquisition
Mydecine Innovations Group Inc. acquired 100% interest in MindLeap's Digital Telehealth Platform focused on the emerging psychedelics industry, to unlock synergies between the two companies.
Additional Mydecine Subsidiaries
NeuroPharm Inc.
NeuroPharm Inc. (NPI) is developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations.
